Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

AMF Regulated Information

AMF Documents
AMF Press Releases

AMF Documents
AMF Press Releases

AMF Documents

Search Filings

Found 191 Results

Page 1 of 2012 3 4 5...10 20...»Last »

March 3, 2026

Information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2026

January 12, 2026

Update – Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

January 5, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

December 2, 2025

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2025

November 3, 2025

Information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2025

May 6, 2025

Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025

April 9, 2025

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2025

March 28, 2025

Information Document Annex IX

December 2, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024

October 14, 2024

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

Page 1 of 2012 3 4 5...10 20...»Last »

Latest AMF Press Releases

January 6, 2026

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

July 28, 2025

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

June 11, 2025

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

View All Press Releases

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top